{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    13,
    14,
    15,
    19,
    20,
    21
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To determine if axicabtagene ciloleucel is superior to standard of care (SOC) as measured by event-free survival (EFS), as determined by blinded central review",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - ORR",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on objective response rate (ORR), as determined by blinded central review",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - OS",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on overall survival (OS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - PFS",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on progression-free survival (PFS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - DOR",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on duration of response (DOR) and duration of complete response among responding subjects, as determined by blinded central review",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - Safety",
        "text": "To evaluate the safety of axicabtagene ciloleucel compared to SOC",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective - PRO/QoL",
        "text": "To evaluate the effect of axicabtagene ciloleucel on patient reported outcomes (PROs) and quality of life (QoL) compared to SOC",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint - EFS",
        "text": "Event-free Survival (EFS): EFS is defined as the time from randomization to the earliest date of disease progression per the Lugano Classification {Cheson 2014}, commencement of new lymphoma therapy, or death from any cause.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Endpoint - ORR",
        "text": "Objective response rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Key Secondary Endpoint - OS",
        "text": "Overall survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Endpoint - Investigator EFS",
        "text": "EFS based on investigator disease assessments",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Endpoint - Modified EFS",
        "text": "Modified EFS based on blinded central review and on investigator disease assessments",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint - PFS",
        "text": "Progression-free survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Endpoint - DOR/CR",
        "text": "Duration of response and complete response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Endpoint - Safety",
        "text": "Incidence of adverse events and clinically significant changes in safety lab values, including antibodies to axicabtagene ciloleucel",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "Secondary Endpoint - QoL EORTC",
        "text": "Changes from screening to post baseline in the global health status QoL scale and the physical functioning domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC QLQ-C30)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Secondary Endpoint - QoL EQ-5D-5L",
        "text": "Changes from screening to post baseline in the Euro-QOL, Five Dimensions, Five Levels (EQ-5D-5L) index and visual analog scale (VAS) scores",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - EFS",
        "populationSummary": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after first-line rituximab and anthracycline-based chemotherapy (ITT population) Summary measure: Hazard ratio (stratified log-rank test).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Commencement of new lymphoma therapy",
            "text": "Subject starts a new lymphoma therapy before a progression event or death",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death from any cause prior to disease progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues the assigned treatment arm (e.g., fails to receive CAR T infusion or fails to proceed to ASCT)",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Axicabtagene ciloleucel (single infusion of 2 x 10^6 anti-CD19 CAR T cells/kg) vs Standard of Care (SOC) therapy (platinum-based salvage chemotherapy followed by HDT-ASCT for responders)",
        "analysisPopulation": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after first-line rituximab and anthracycline-based chemotherapy (ITT population)",
        "variableOfInterest": "Event-free survival (EFS), defined as the time from randomization to the earliest date of disease progression (per Lugano 2014), commencement of new lymphoma therapy, or death from any cause",
        "summaryMeasure": "Hazard ratio (stratified log-rank test)"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Efficacy Estimand - ORR",
        "populationSummary": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population) Summary measure: Odds ratio (stratified Cochran-Mantel-Haenszel test).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Death prior to response assessment",
            "text": "Subject dies before the first scheduled disease assessment",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_5",
            "name": "Treatment switching",
            "text": "Subject in SOC arm receives CAR T-cell therapy off-protocol",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Axicabtagene ciloleucel vs Standard of Care (SOC)",
        "analysisPopulation": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population)",
        "variableOfInterest": "Objective response rate (ORR), defined as the proportion of subjects achieving a best response of CR or PR",
        "summaryMeasure": "Odds ratio (stratified Cochran-Mantel-Haenszel test)"
      },
      {
        "id": "est_3",
        "name": "Key Secondary Efficacy Estimand - OS",
        "populationSummary": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population) Summary measure: Hazard ratio (stratified log-rank test).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment switching/Crossover",
            "text": "Subjects in the SOC arm receiving subsequent cellular therapy",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Axicabtagene ciloleucel vs Standard of Care (SOC)",
        "analysisPopulation": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population)",
        "variableOfInterest": "Overall survival (OS), defined as the time from randomization to death from any cause",
        "summaryMeasure": "Hazard ratio (stratified log-rank test)"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 6,
      "exploratoryObjectives": 0,
      "totalEndpoints": 10,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To determine if axicabtagene ciloleucel is superior to standard of care (SOC) as measured by event-free survival (EFS), as determined by blinded central review",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - ORR",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on objective response rate (ORR), as determined by blinded central review",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - OS",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on overall survival (OS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - PFS",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on progression-free survival (PFS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - DOR",
        "text": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on duration of response (DOR) and duration of complete response among responding subjects, as determined by blinded central review",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - Safety",
        "text": "To evaluate the safety of axicabtagene ciloleucel compared to SOC",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective - PRO/QoL",
        "text": "To evaluate the effect of axicabtagene ciloleucel on patient reported outcomes (PROs) and quality of life (QoL) compared to SOC",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint - EFS",
        "text": "Event-free Survival (EFS): EFS is defined as the time from randomization to the earliest date of disease progression per the Lugano Classification {Cheson 2014}, commencement of new lymphoma therapy, or death from any cause.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Endpoint - ORR",
        "text": "Objective response rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Key Secondary Endpoint - OS",
        "text": "Overall survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Endpoint - Investigator EFS",
        "text": "EFS based on investigator disease assessments",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Endpoint - Modified EFS",
        "text": "Modified EFS based on blinded central review and on investigator disease assessments",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint - PFS",
        "text": "Progression-free survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Endpoint - DOR/CR",
        "text": "Duration of response and complete response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Endpoint - Safety",
        "text": "Incidence of adverse events and clinically significant changes in safety lab values, including antibodies to axicabtagene ciloleucel",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "Secondary Endpoint - QoL EORTC",
        "text": "Changes from screening to post baseline in the global health status QoL scale and the physical functioning domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC QLQ-C30)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Secondary Endpoint - QoL EQ-5D-5L",
        "text": "Changes from screening to post baseline in the Euro-QOL, Five Dimensions, Five Levels (EQ-5D-5L) index and visual analog scale (VAS) scores",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - EFS",
        "populationSummary": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after first-line rituximab and anthracycline-based chemotherapy (ITT population) Summary measure: Hazard ratio (stratified log-rank test).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Commencement of new lymphoma therapy",
            "text": "Subject starts a new lymphoma therapy before a progression event or death",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death from any cause prior to disease progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues the assigned treatment arm (e.g., fails to receive CAR T infusion or fails to proceed to ASCT)",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Axicabtagene ciloleucel (single infusion of 2 x 10^6 anti-CD19 CAR T cells/kg) vs Standard of Care (SOC) therapy (platinum-based salvage chemotherapy followed by HDT-ASCT for responders)",
        "analysisPopulation": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after first-line rituximab and anthracycline-based chemotherapy (ITT population)",
        "variableOfInterest": "Event-free survival (EFS), defined as the time from randomization to the earliest date of disease progression (per Lugano 2014), commencement of new lymphoma therapy, or death from any cause",
        "summaryMeasure": "Hazard ratio (stratified log-rank test)"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Efficacy Estimand - ORR",
        "populationSummary": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population) Summary measure: Odds ratio (stratified Cochran-Mantel-Haenszel test).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Death prior to response assessment",
            "text": "Subject dies before the first scheduled disease assessment",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_5",
            "name": "Treatment switching",
            "text": "Subject in SOC arm receives CAR T-cell therapy off-protocol",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Axicabtagene ciloleucel vs Standard of Care (SOC)",
        "analysisPopulation": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population)",
        "variableOfInterest": "Objective response rate (ORR), defined as the proportion of subjects achieving a best response of CR or PR",
        "summaryMeasure": "Odds ratio (stratified Cochran-Mantel-Haenszel test)"
      },
      {
        "id": "est_3",
        "name": "Key Secondary Efficacy Estimand - OS",
        "populationSummary": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population) Summary measure: Hazard ratio (stratified log-rank test).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment switching/Crossover",
            "text": "Subjects in the SOC arm receiving subsequent cellular therapy",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Axicabtagene ciloleucel vs Standard of Care (SOC)",
        "analysisPopulation": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (ITT population)",
        "variableOfInterest": "Overall survival (OS), defined as the time from randomization to death from any cause",
        "summaryMeasure": "Hazard ratio (stratified log-rank test)"
      }
    ]
  }
}